Kura Oncology (NASDAQ:KURA) SVP Thomas James Doyle Sells 4,541 Shares

Key Points

• Thomas James Doyle, the Senior Vice President of Kura Oncology, sold 4,541 shares for a total of $40,596.54, reducing his ownership by 3.97%.
• Kura Oncology reported a significant loss of ($0.75) earnings per share, missing the consensus estimate by ($0.90), and generated $15.29 million in revenue, below expectations of $64.95 million.
• Analysts have set a consensus rating of "Moderate Buy" for Kura Oncology, with an average price target of $24.10, reflecting varying outlooks from multiple research firms.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) SVP Thomas James Doyle sold 4,541 shares of the company's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $8.94, for a total value of $40,596.54. Following the completion of the sale, the senior vice president owned 109,829 shares in the company, valued at $981,871.26. This represents a 3.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kura Oncology Price Performance

Shares of NASDAQ:KURA traded down $0.08 on Monday, hitting $8.97. The company had a trading volume of 2,168,205 shares, compared to its average volume of 1,613,537. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 52-week low of $5.41 and a 52-week high of $19.93. The business has a 50 day moving average of $7.39 and a 200 day moving average of $6.65. The company has a market cap of $778.60 million, a PE ratio of -3.97 and a beta of 0.19.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on KURA shares. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kura Oncology in a research note on Friday, June 20th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. JMP Securities lowered their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research note on Monday, August 11th. Guggenheim began coverage on Kura Oncology in a research note on Thursday, September 4th. They set a "neutral" rating for the company. Finally, Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of "Moderate Buy" and an average target price of $24.10.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the stock. State of Wyoming bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $48,000. Pallas Capital Advisors LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $66,000. Tower Research Capital LLC TRC lifted its holdings in shares of Kura Oncology by 471.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company's stock worth $70,000 after purchasing an additional 9,958 shares during the last quarter. Flower City Capital bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $79,000. Finally, Magnetar Financial LLC bought a new stake in shares of Kura Oncology in the 1st quarter worth approximately $79,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.